Tuglif-S
BRAND NAME:
Tuglif-S
GENERIC NAME:
Ertugliflozin + Sitagliptin HCl
THERAPEUTIC SEGMENT:
Antidiabetic
INDICATIONS:
Tuglif-S is a combination of ertugliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, and sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
BRIEF DESCRIPTION:
Ertugliflozin + Sitagliptin is an orally bioavailable, fixed-dose combination therapy for the management of type 2 diabetes mellitus (T2DM). Ertugliflozin, a sodium-glucose co-transporter-2 (SGLT2) inhibitor, lowers blood glucose by inhibiting renal glucose reabsorption, promoting glycosuria, and providing additional benefits such as weight reduction and blood pressure control. Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances incretin hormone activity, leading to glucose-dependent insulin secretion and reduced glucagon levels, thereby improving postprandial glycemic control. This combination targets multiple pathways of glucose regulation, offering effective glycemic management with a low risk of hypoglycemia and potential cardiovascular benefits.
DOSAGE FORM:
Tablets
5mg+100mg
15mg+100mg
Disclaimer: For use under medical prescription only
Reviews
There are no reviews yet.